hline1.jpg (2302 bytes) PRESS ROOM hline1.jpg (2302 bytes)
Aurobindo receives first tentative approval for Stavudine Oral Solution from US FDA
Aurobindo's 6 ARV products in World Health Organization (WHO) Pre-qualification list
Aurobindo selected for Patent Appreciation Award by IDMA
Aurobindo's receives final approval of Mirtazapine Orally Disintegrating Tablets
Aurobinoo's product included in World Health Organization (WHO) Pre-qualification list
Aurobindo receives approval for Amoxicillin Tablets & Capsules
Aurobindo receives tentative approval for Lamivudine Oral Solution from UD FDA
Aurobindo Q2 Revenue Improves to Rs.3271 Million.
- growth of over 20%
Aurobindo gets EDQM approval for Flucloxacillin Sodium
US FDA grants tentative approval for Aurobindo's Sertraline
US FDA grants approval for Aurobindo's zidovudine
Aurobindo receives tentative approval for zidovudine tablet
Aurobindo’s products included in World Health Organization (WHO) Pre-qualification list
Aurobindo’s scientist conferred award
Aurobindo posts revenue of Rs.2807 Million in Q1.
Aurobindo gets EDQM approval for Domperidone & Domperidone Maleate
Canadian authority approves Aurobindo’s facilities
Aurobindo Pharma gets US FDA nod for lamivudine and zidovudine combination tablets
Aurobindo receives - first generic approval of Efavirenz
Aurobindo announces approval of Stavudine tablets
Aurobindo records revenue of Rs.11592 Million. Record facility approvals, DMFs/ANDAs filings and significant R & D expenses weigh on Aurobindo's bottom line
Aurobindo receives second ANDA approval from US FDA for PEPFAR
Aurobindo receives the first ARV approval from US FDA
USFDA approval received for Unit VIII Facility
Aurobindo receives NABL approval for its Clinical Laboratory
Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3rd product approval from USFDA
Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies
Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.
Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2
First product approval from US FDA received
Foray into Regulated Market crosses first major milestone
Company scientists conferred awards
Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31st July 2004
Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit
Aurobindo net profit at Rs. 127 crs surges by 23%
UK MHRA (UK MCA) approval received for Unit 3
Subscription to preferential issue of equity shares
Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales
Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram
Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%
Preferential Issue of Equity Shares
Aurobindo net profit spurts by 52.75% in Q1
Aurobindo crosses the landmark Net Profit of Rs.100 crores
Aurobindo's demonstration of R&D leadership in cephalosporins
Aurobindo Pharma launches cefepime
Second quarter profit jumps  41.13%
Aurobindo implementing ERP package
First quarter profit jumps 34%
Aurobindo posts Net Profit of  Rs. 68.51 crores
Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board
Aurobindo Pharma wins award for the best bulk drug company
Shares allotted to Templeton
Brazilian GMP certification received for the speciality generic formulations unit
Aurobindo Pharma acquires equity in Ranit Pharma
Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma
Aurobindo Pharma launches Aztreonam for the first time in India  
Aurobindo Pharma & Citadel promote a joint venture  
Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget
Aurobindo launches Cefactam (Cefoperazone plus Salbactam)
4th generation Cephalosporin – Cefpirome launched
Impressive Q3 performance 
Aurobindo shareholders approve Rs.125 crore Private Placement
Templeton to pick up equity
Aurobindo Pharma Board approves Rs. 125 crore private placement
Aurobindo Pharma launches two more antiretroviral products for HIV treatment
Restructuring on track
Aurobindo introduces two more drugs for treatment of Aids
Imunus Aurobindo launches two new anti-aids drugs
Aurobindo Pharma slashes prices of anti-aids drugs
Restructuring of Facilities
Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 21st November, 2005
AUROBINDO RECEIVES APPROVAL FOR CEPHALEXIN CAPSULES BY US FDA

 
Aurobindo Pharma Limited is pleased to announce that U.S. Food Drug Administration (US FDA) has approved its Cephalexin capsules USP 250 mg & 500 mg.
Aurobindo achieved another major milestone by obtaining the first product approval from the dedicated Cephalosporin facility (Unit VI, situated in Medak District, Andhrapradesh, India).
Aurobindo has set up three (Unit III, Unit VI, Unit XII) multi module formulation manufacturing facilities. Earlier products from Unit III only contributed to the sales in the US.  Product approvals from Unit XII and Unit VI have taken place in the last few days and Aurobindo will be in a position to capitalize on this opportunity with immediate effect.
The market opportunity for the Cephalexin Capsules USP 250 mg and 500 mg is around USD 80 million.
Aurobindo is the proven leader in this segment/product range in several markets in the world and is looking forward to market its range in USA.
Unit Segments Certifications
Unit I
Unit IA		 CVS, CNS, anti-allergics
Cephs		 US FDA
US FDA
Unit VIII
Unit VI		 Gastro enterologivals, ARV's
Cephs		 US FDA, WHO
Health Canada
Unit VA
Unit XI A		 SSP's
ARV's		 Awaiting US FDA
approvals
 

Formulations

  
Unit III Oral solids
Liquids		 Multi purpose
-do-		 US FDA, UK MHRA, WHO, Health Canada, MCC (SA) & ANVISA
US FDA, Health Canada
Unit VI B
Liquids		 Cephs US FDA, MCC,
Health Canada
Unit XII
Liquids		 SSPs Health Canada, US FDA
Bio-equivalence centre   US FDA, Brazil
ANVISA, WHO
About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing (Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) around 65 APIs in the non-antibiotics and 55 APIs in the antibiotic segment. The Company is marketing these products globally, in over 100 countries.

Top

________________________________________________________________